IDH1 and acute myeloid leukemia: Patients with IDH1/2-mutant AML treated with venetoclax-based combinations have enjoyed not only higher and more durable responses, but also longer survival compared to the global population of each study (median OS was 19.4 months and 24.4 months, with LDAC and HMA, respectively) which is on par with azacitidine + ivosidenib or azacitidine + enasidenib studies (49, 50).